Paula F. Orlandi

Paula F. Orlandi

Auto-generated profile, based on publicly available information

Paula F. Orlandi

Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2018 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
TIthe CRIC Study Investigators
the CRIC Study Investigators
POPaula F. Orlandi
Paula F. Orlandi
NFNaohiko Fujii
Naohiko Fujii
JRJason Roy
Jason Roy
HCHsiang-Yu Chen
Hsiang-Yu Chen
HFHarold I. Feldman
Harold I. Feldman
Hematuria is associated with chronic kidney disease (CKD), but has rarely been examined as a risk factor for CKD progression. We explored whether individuals with hematuria had worse outcomes compared to those without hematuria in the CRIC Study. Participants were a racially and ethnically diverse group of adults (21 to 74 years), with moderate CKD. Presence of hematuria (positive dipstick) from a single urine sample was the primary predictor. Outcomes included a 50% or greater reduction in eGFR from baseline, ESRD, and death, over a median follow-up of 7.3 years, analyzed using Cox Proportional Hazards models. Net reclassification indices (NRI) and C statistics were calculated to evaluate their predictive performance. Hematuria was observed in 1145 (29%) of a total of 3272 participants at baseline. Individuals with hematuria were more likely to be Hispanic (22% vs. 9.5%, respectively), have diabetes (56% vs. 48%), lower mean eGFR (40.2 vs. 45.3 ml/min/1.73 m2), and higher levels of urinary albumin > 1.0 g/day (36% vs. 10%). In multivariable-adjusted analysis, individuals with hematuria had a greater risk for all outcomes during the first 2 years of follow-up: Halving of eGFR or ESRD (HR Year 1: 1.68, Year 2: 1.36), ESRD (Year 1: 1.71, Year 2: 1.39) and death (Year 1:1.92, Year 2: 1.77), and these associations were attenuated, thereafter. Based on NRIs and C-statistics, no clear improvement in the ability to improve prediction of study outcomes was observed when hematuria was included in multivariable models. In a large adult cohort with CKD, hematuria was associated with a significantly higher risk of CKD progression and death in the first 2 years of follow-up but did not improve risk prediction.

6 October 2020 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
POPaula F. Orlandi
Paula F. Orlandi
DXDawei Xie
Dawei Xie
WYWei Yang
Wei Yang
JCJordana B. Cohen
Jordana B. Cohen
RDRajat Deo
Rajat Deo
TIthe CRIC Study Investigators
the CRIC Study Investigators
Significance Statement: Among individuals with CKD, decreases in eGFR, or increases that are steeper than the average loss, have been associated with increased risks of death and cardiovascular events. Sarcopenia and chronic illness might explain why apparent eGFR improvement relates to poor outcomes. The authors investigated the association between slopes of eGFR (defined with yearly eGFR) and the risks of death and cardiovascular events in a prospective cohort of adults with CKD. They found that declines in eGFR greater than the average eGFR loss were associated with increased risks of death and cardiovascular events, despite multiple adjustments. However, neither rises in eGFR nor losses smaller than the average eGFR loss were associated with increases in such risks. These findings suggest that, in CKD, improving eGFR might not be associated with concerning outcomes. Background: Slopes of eGFR have been associated with increased risks of death and cardiovascular events in a U-shaped fashion. Poor outcomes in individuals with rising eGFR are potentially attributable to sarcopenia, hemodilution, and other indicators of clinical deterioration. Methods: To investigate the association between eGFR slopes and risks of death or cardiovascular events, accounting for multiple confounders, we studied 2738 individuals with moderate to severe CKD participating in the multicenter Chronic Renal Insufficiency Cohort (CRIC) Study. We used linear, mixed-effects models to estimate slopes with up to four annual eGFR assessments, and Cox proportional hazards models to investigate the association between slopes and the risks of death and cardiovascular events. Results: Slopes of eGFR had a bell-shaped distribution (mean [SD], −1.5 [−2] ml/min per 1.73 m2 per year). Declines of eGFR that were steeper than the average decline associated with progressively increasing risks of death (hazard ratio [HR], 1.23; 95% confidence interval [95% CI], 1.09 to 1.39; for a slope 1 SD below the average) and cardiovascular events (HR, 1.19; 95% CI, 1.03 to 1.38). Rises of eGFR or declines lower than the average decline were not associated with the risk of death or cardiovascular events. Conclusions: In a cohort of individuals with moderate to severe CKD, we observed steep declines of eGFR were associated with progressively increasing risks of death and cardiovascular events; however, we found no increased risks associated with eGFR improvement. These findings support the potential value of eGFR slopes in clinical assessment of adults with CKD.

1 November 2019 in Kidney International
Verified
Journal Article
Closed access
POPaula F. Orlandi
Paula F. Orlandi
JHJing Huang
Jing Huang
MFMasafumi Fukagawa
Masafumi Fukagawa
WHWendy Hoy
Wendy Hoy
VJVivekanand Jha
Vivekanand Jha
VKVivek Kumar
Vivek Kumar